Wee Joo Chng
Wee Joo Chng
Cancer Science Institute of Singapore
Verified email at nus.edu.sg
Title
Cited by
Cited by
Year
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ...
Cancer cell 12 (2), 131-144, 2007
10132007
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
9122016
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
7182012
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
5832016
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ...
Nature medicine 18 (4), 521, 2012
5362012
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood 127 (24), 2955-2962, 2016
4512016
IMWG consensus on risk stratification in multiple myeloma
WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, ...
Leukemia 28 (2), 269-277, 2014
4332014
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
G Mulligan, C Mitsiades, B Bryant, F Zhan, WJ Chng, S Roels, E Koenig, ...
Blood 109 (8), 3177-3188, 2007
3602007
Genetic aberrations and survival in plasma cell leukemia
RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ...
Leukemia 22 (5), 1044-1052, 2008
3222008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
M Chesi, DF Robbiani, M Sebag, WJ Chng, M Affer, R Tiedemann, ...
Cancer cell 13 (2), 167-180, 2008
3122008
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
WJ Chng, S Kumar, S VanWier, G Ahmann, T Price-Troska, K Henderson, ...
Cancer research 67 (7), 2982-2989, 2007
2532007
Telomerase directly regulates NF-κB-dependent transcription
A Ghosh, G Saginc, SC Leow, E Khattar, EM Shin, TD Yan, M Wong, ...
Nature cell biology 14 (12), 1270-1281, 2012
2412012
Management of treatment-emergent peripheral neuropathy in multiple myeloma
PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ...
Leukemia 26 (4), 595-608, 2012
2402012
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ...
Leukemia 28 (3), 525-542, 2014
2332014
Genetic events in the pathogenesis of multiple myeloma
WJ Chng, O Glebov, PL Bergsagel, WM Kuehl
Best practice & research Clinical haematology 20 (4), 571-596, 2007
2272007
P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation
XL Li, J Zhou, ZR Chen, WJ Chng
World journal of gastroenterology: WJG 21 (1), 84, 2015
2242015
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
WJ Chng, GF Huang, TH Chung, SB Ng, N Gonzalez-Paz, T Troska-Price, ...
Leukemia 25 (6), 1026-1035, 2011
2162011
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
MA Dimopoulos, H Goldschmidt, R Niesvizky, D Joshua, WJ Chng, A Oriol, ...
The Lancet Oncology 18 (10), 1327-1337, 2017
2082017
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R Fonseca, SA Van Wier, WJ Chng, R Ketterling, MQ Lacy, A Dispenzieri, ...
Leukemia 20 (11), 2034-2040, 2006
2052006
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ...
The Lancet Oncology 18 (4), e206-e217, 2017
2042017
The system can't perform the operation now. Try again later.
Articles 1–20